BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37491169)

  • 21. One-level step section histological analysis is insufficient to confirm complete pathological response after neoadjuvant chemoradiation for rectal cancer.
    Pereira MA; Dias AR; Faraj SF; Nahas CSR; Imperiale AR; Marques CFS; Cotti GC; Azevedo BC; Nahas SC; de Mello ES; Ribeiro U
    Tech Coloproctol; 2017 Sep; 21(9):745-754. PubMed ID: 28819868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy.
    Wang QX; Zhang R; Xiao WW; Zhang S; Wei MB; Li YH; Chang H; Xie WH; Li LR; Ding PR; Chen G; Zeng ZF; Wang WH; Wan XB; Gao YH
    Radiat Oncol; 2021 Jan; 16(1):16. PubMed ID: 33468176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Watch-and-Wait Compared to Operation for Patients with Complete Response to Neoadjuvant Therapy for Rectal Cancer.
    Beard BW; Rettig RL; Ryoo JJ; Parker RA; McLemore EC; Attaluri V
    J Am Coll Surg; 2020 Dec; 231(6):681-692. PubMed ID: 33121903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study.
    Li J; Liu H; Yin J; Liu S; Hu J; Du F; Yuan J; Lv B; Fan J; Leng S; Zhang X
    Oncotarget; 2015 Dec; 6(39):42354-61. PubMed ID: 26472284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Predictive value of combination of MRI tumor regression grade and apparent diffusion coefficient for pathological complete remission after neoadjuvant treatment of locally advanced rectal cancer].
    Xu N; Huang FC; Li WL; Luan X; Jiang YM; He B
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):359-365. PubMed ID: 33878826
    [No Abstract]   [Full Text] [Related]  

  • 26. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation.
    Habr-Gama A; Lynn PB; Jorge JM; São Julião GP; Proscurshim I; Gama-Rodrigues J; Fernandez LM; Perez RO
    Dis Colon Rectum; 2016 Apr; 59(4):264-9. PubMed ID: 26953984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgery may not benefit patients with locally advanced rectal cancer who achieved clinical complete response following neoadjuvant chemoradiotherapy.
    Han Z; Li M; Chen J; Ji D; Zhan T; Peng Y; Xue W; Li Y; Cai Y; Sun Y; Wu Q; Du C; Gu J
    Asian J Surg; 2022 Jan; 45(1):97-104. PubMed ID: 33888366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The impact of extended waiting time on tumor regression after neoadjuvant chemoradiotherapy for locally advanced rectal cancer].
    Zheng K; Jin L; Shen F; Gao XH; Zhu XM; Yu GY; Hao LQ; Lou Z; Wang H; Yu ED; Bai CG; Zhang W
    Zhonghua Wai Ke Za Zhi; 2023 Sep; 61(9):775-781. PubMed ID: 37491170
    [No Abstract]   [Full Text] [Related]  

  • 32. Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial.
    Marchegiani F; Palatucci V; Capelli G; Guerrieri M; Belluco C; Rega D; Morpurgo E; Coco C; Restivo A; De Franciscis S; Aschele C; Perin A; Bonomo M; Muratore A; Spinelli A; Ramuscello S; Bergamo F; Montesi G; Spolverato G; Del Bianco P; Gambacorta MA; Delrio P; Pucciarelli S
    Ann Surg Oncol; 2022 Mar; 29(3):1880-1889. PubMed ID: 34855063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Rational evaluation of the complete response after neoadjuvant therapy in locally advanced mid-low rectal cancer: the pros and cons of "watch and wait" strategy].
    Gu J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):507-513. PubMed ID: 31238630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy.
    Smith JJ; Strombom P; Chow OS; Roxburgh CS; Lynn P; Eaton A; Widmar M; Ganesh K; Yaeger R; Cercek A; Weiser MR; Nash GM; Guillem JG; Temple LKF; Chalasani SB; Fuqua JL; Petkovska I; Wu AJ; Reyngold M; Vakiani E; Shia J; Segal NH; Smith JD; Crane C; Gollub MJ; Gonen M; Saltz LB; Garcia-Aguilar J; Paty PB
    JAMA Oncol; 2019 Apr; 5(4):e185896. PubMed ID: 30629084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
    Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
    Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
    Perez RO; Habr-Gama A; Lynn PB; São Julião GP; Bianchi R; Proscurshim I; Gama-Rodrigues J
    Dis Colon Rectum; 2013 Jan; 56(1):6-13. PubMed ID: 23222274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes of real world 'watch and wait' data for rectal cancer after neoadjuvant chemoradiotherapy.
    Simpson G; Hopley P; Wilson J; Day N; Haworth A; Montazeri A; Smith D; Titu L; Anderson J; Agbamu D; Walsh C
    Colorectal Dis; 2020 Nov; 22(11):1568-1576. PubMed ID: 32686268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage Surgery With Organ Preservation for Patients With Local Regrowth After Watch and Wait: Is It Still Possible?
    Fernandez LM; Figueiredo NL; Habr-Gama A; São Julião GP; Vieira P; Vailati BB; Nasir I; Parés O; Santiago I; Castillo-Martin M; Carvalho C; Parvaiz A; Perez RO
    Dis Colon Rectum; 2020 Aug; 63(8):1053-1062. PubMed ID: 32692070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
    Li D; Wu H; Feng R; Zhong D; Luo Y; Xiao Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):690-4. PubMed ID: 27353106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.